identified and characterized tumor-specific Th1-skewed CD4+ T cells targeting multiple neoantigens in a MCPyV-negative MCC patient who achieved a profound and durable partial response to anti-PD-L1 therapy (74). Here, CD4 is linked to neoplasm.